MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
October 28 2021 - 10:00AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider
of enabling platform technologies for ex-vivo cell engineering,
today announces the signing of a strategic platform license (SPL)
with Nkarta, Inc., a biopharmaceutical company developing
engineered natural killer (NK) cell therapies to treat cancer.
Under the terms of the agreement, Nkarta obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
The Nkarta approach maximizes the therapeutic
effect of allogeneic NK cells through robust expansion, enhanced
targeting and extended persistence resulting in potent immune cells
that enable a sustained anti-cancer immune-mediated attack.
“Broad access to the most powerful and promising
enabling technologies is critical to our success and the innovation
of next-generation NK cell therapies for cancer patients,” said
Paul J. Hastings, Nkarta’s President and CEO.
“MaxCyte’s electroporation technology leads the field and we’re
excited to leverage the advantages of their transfection technology
with our integrated cell engineering platform.”
Doug Doerfler, President and CEO of
MaxCyte, said: “We are proud to support Nkarta’s
pioneering platform that has the potential to boost the body’s
immune response to fight cancer. Our team is thrilled to be working
with a leader in developing novel products leveraging the unique
power of NK cells for the treatment of patients with cancer.”
MaxCyte’s ExPERT™ instrument portfolio is the
next generation of leading, clinically-validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Nkarta, Inc. is MaxCyte’s 15th SPL adding to
three MaxCyte partnerships year-to-date, which generate
pre-commercial milestone revenue and the vast majority of which
include post-commercial revenue.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: three instruments, the ATx™,
STx™ and GTx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte
Contacts: |
|
US IR
Adviser |
|
Gilmartin
GroupDavid Deuchler, CFA |
+1
415-937-5400 ir@maxcyte.com |
|
|
US Media
Relations |
|
Laura MorganSam Brown Healthcare
Communications |
+1
951-333-9110lauramorgan@sambrown.com |
|
|
Nominated Adviser and
Joint Corporate Broker |
|
Panmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR
Adviser |
|
Consilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024